It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms.
A lzheimer disease (AD) is defined at the neuropathological molecular level by amyloid plaques and neurofibrillary tangles. 1, 2 This neuropathology generally follows a characteristic spatial distribution, with amyloid plaques beginning in neocortical association regions and tangles beginning in the medial temporal lobe and then spreading into adjacent association cortices with subsequent pancortical extension. 3, 4 Presenilin 1 (PSEN1; OMIM, 104311) mutations predispose individuals to develop autosomal dominant Alzheimer disease (ADAD), usually relatively early in adulthood. 5 While the pathogenesis of ADAD may be different from late-onset AD (LOAD) and some clinical features may differ, these conditions are markedly similar in terms of their biological profiles, including abnormalities in amyloid biomarkers, brain structure, and brain activity. 6 Biomarker investigations of families with ADAD have already shed light on the trajectory of ADrelated brain changes, especially prior to the onset of clinical symptoms. [6] [7] [8] In addition, ongoing studies of these families will inform the design of future prevention clinical trials for individuals at risk for AD. We used brain imaging and other biomarker measures to detect changes in preclinical PSEN1 E280A (Glu280Ala) mutation carriers from the largest known ADAD kindred. Residing in Antioquia, Colombia, this kindred is estimated to have approximately 5000 living members, including approximately 1800 mutation carriers. 9 Approximately 30% of living mutation carriers from this kindred are currently experiencing symptoms of AD, with median ages of 44 years (95% CI, 43-45) at onset of mild cognitive impairment (MCI) and 49 years (49-50) at onset of dementia. 9 These carriers show evidence of preclinical AD in the years and decades before their estimated clinical onset, including elevated cortical amyloid levels, lower cerebral metabolic rates for glucose, smaller hippocampal volumes, lower cerebrospinal fluid β-amyloid (Aβ) 1-42 levels, higher cerebrospinal fluid total tau and tau phosphorylated at threonine 181 levels, and higher plasma Aβ1-42 measurements. 6 In fact, even children and young adults with PSEN1 E280A mutations have alterations in magnetic resonance imaging measurements of brain structure 7, 10 and function (eg, hippocampal hyperactivation and less precuneus deactivation) more than 2 decades prior to the kindred's median age of MCI onset. 7, 10 Recently, it has become possible to investigate the aggregation of tau in vivo using positron emission tomography (PET) imaging. This novel biomarker holds promise for detecting AD in the preclinical stage. Examination of tau PET in ADAD is particularly relevant to understanding the aggregation and spreading of tau in AD without the major confounders of aging and comorbidities that often exist in sporadic AD. Additionally, the study of tau PET in combination with Pittsburgh Compound B (PiB) PET measures can reveal the extent to which amyloidtau relations in ADAD differ from those seen in sporadic AD. To our knowledge, tau imaging has not been extensively tested in ADAD to date.
In this study, we used PET imaging to characterize amyloid burden and tau accumulation as well as the association between the 2 in the brains of young PSEN1 E280A mutation carriers. We hypothesized that, similar to what has been reported in individuals with LOAD, 11 PSEN1 mutation carriers would have abnormal levels of Aβ before evidence of tau tangle formation as measured by PET imaging both within and beyond the medial temporal lobe.
Methods

Study Design and Participants
This cross-sectional study collected PET images using 2 radioligands, flortaucipir F 18 (18F FTP; previously known as AV 1451, T807), which selectively binds tau aggregates, and carbon 11-labeled PiB, which selectively binds amyloid deposits, in individuals with and without the PSEN1 E280A mutation. These images were compared with each other and with neuropsychological data. Volunteers were recruited from the Colombian Alzheimer Prevention Initiative registry, which currently includes more than 5000 living members of the PSEN1 E280A kindred. The participants selected for the present study, both carriers and noncarriers, descended from a common ancestor, and their ages ranged from 28 to 55 years. Only participants living in the metropolitan area of the Aburra Valley within 105 miles of the University of Antioquia, Medellin, Antioquia, Colombia, were invited to participate in the study. Potential participants were screened in advance for the presence of neurological and psychiatric disorders, drug use, and eligibility to undergo magnetic resonance imaging. Participants provided written informed consent before enrollment into study procedures. Participants were studied under guidelines approved by local institutional review boards. Ethics approval was obtained from the University of Antioquia Ethics Committee for procedures undertaken in Colombia and the Massachusetts General Hospital Institutional Review Board for procedures undertaken in the United States. All data were acquired by investigators who were masked to the participants' genetic status.
Cognitively unimpaired participants had to show no cognitive impairment on a standard cognitive battery, including
Key Points
Question Does cortical β-amyloid deposition precede tau tangle formation within and beyond the medial temporal lobe in individuals with autosomal dominant Alzheimer disease?
Findings In this cross-sectional study that included 24 members of a Colombian kindred with autosomal dominant Alzheimer disease, elevated tau levels were seen in regions of the medial temporal lobe in unimpaired presenilin 1 E280A mutation carriers in their late 30s, and significant tau tangle formation in neocortical regions was observed in 1 cognitively unimpaired carrier as well as in those with mild cognitive impairment.
Meaning These findings add to the growing evidence that tau positron emission tomography imaging may be useful to characterize biological changes associated with Alzheimer disease in cognitively unimpaired individuals and to track disease progression. 
Image Acquisition and Processing
Flortaucipir F 18 was prepared at Massachusetts General Hospital with a mean (SD) radiochemical yield of 14% (3%) and a mean (SD) specific activity of 216 (60) GBq/μmol at the end of synthesis (60 min) and was validated for human use. 16 Carbon 11-labeled PiB was prepared and PET images were acquired as described previously. 17 All PET images were acquired using a Siemens/CTI ECAT PET HR scanner (3-dimensional mode; 63 image planes; 15.2-cm axial field of view; 5.6-mm transaxial resolution; and 2.4-mm slice interval). Carbon 11-labeled PiB PET was acquired with a 8.5-to 15.0-mCi bolus injection followed immediately by a 60-minute dynamic acquisition in 69 frames (12 × 15 seconds, 57 × 60 seconds). Flortaucipir F 18 was acquired from 80 to 100 minutes after a 9.0-to 11.0-mCi bolus injection in 4 × 5-minute frames. Positron emission tomography images were reconstructed and attenuation-corrected, and each frame was evaluated to verify adequate count statistics and absence of head motion. All imaging was done within the span of 1 week. Cognitive testing was conducted within 2 months of imaging acquisitions. Magnetic resonance imaging was performed on a MAGNETOM Tim Trio 3-T scanner (Siemens) and included a magnetization-prepared rapid gradient-echo processed with FreeSurfer image analysis suite version 5.0 to identify gray and white matter and pial surfaces to permit region of interest (ROI) parcellation for cerebellar gray matter, hippocampus, and the following Braak stage-related cortices: entorhinal, parahippocampal, inferior temporal, fusiform, and posterior cingulate, as described previously. 11, [17] [18] [19] To evaluate the anatomical distribution of cortical FTP binding, each individual PET data set was rigidly coregistered to the individual's magnetization-prepared rapid gradient-echo magnetic resonance data using statistical parametric mapping (SPM8; Wellcome Trust Centre for Neuroimaging). The cortical ribbon and subcortical ROIs defined by magnetic resonance imaging as described above were transformed into the PET native space; PET data were sampled within each rightleft ROI pair. Standardized uptake value ratio (SUVR) values were represented graphically on vertices at the pial surface. Positron emission tomography data were not partial volume corrected.
Flortaucipir F 18-specific binding was expressed in FreeSurfer ROIs as the SUVR to cerebellum, similar to a previous report, 11 using the FreeSurfer cerebellar gray matter ROI as the reference. For voxelwise analyses, each individual's magnetization-prepared rapid gradient-echo was registered to the template magnetic resonance in SPM8, and the spatially transformed SUVR PET data were smoothed with a 8-mm Gaussian kernel to account for individual anatomic differences. 20 To account for possible 18F FTP off-target binding in choroid plexus, which may confound hippocampal signal, we used a linear regression to regress the choroid plexus, as previously reported.
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Carbon 11-labeled PiB PET data were expressed as the distribution volume ratio (DVR) with cerebellar gray matter as the reference tissue; regional time-activity curves were used to compute regional DVRs for each ROI using the Logan graphical method 22 applied to data from 40 to 60 minutes after injection. 17 Carbon 11-labeled PiB retention was assessed using a large cortical ROI aggregate that included frontal, lateral temporal, and retrosplenial cortices, as described previously.
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Statistical Analyses
Flortaucipir F 18 SUVRs in mutation carriers and noncarriers were compared both voxelwise and within FreeSurferdefined ROIs. The Mann-Whitney U test was used to compare PET ROI measures between groups. Positron emission tomography ROI measures in each group were correlated with age using Spearman rho. Carbon 11-labeled PiB frontal, lateral temporal, and retrosplenial cortices were used as a continuous measure of Aβ levels, and amyloid-positive was defined as a DVR greater than 1.2 in the frontal, lateral temporal, and retrosplenial cortices. 25 Correlations between mean cortical PiB and inferior temporal 18F FTP measures as well as relationships with age and neuropsychological test scores were evaluated with Spearman rho. This includes preferential PiB binding in the posterior cingulate, precuneus, parietotemporal, frontal, and basal ganglia regions. Given the possible confounders of using the cerebellum as the reference region, 27,28 we also performed the PiB and FTP analyses using white matter as a reference. Results with white matter were very similar to the results using the cerebellum (eg, the statistical differences observed with cerebellum as the reference region were also observed with white matter as the reference).
Results
Demographic Information
Regional 18F FTP Binding in PSEN1 Mutation Carriers Figure 1 , and group comparisons are shown in Figure 2 . 
Associations Among PET Measures, Age, and Cognitive Measures
In mutation carriers, greater age was associated with both higher cortical PiB DVR (r = 0.88; P < .001) and higher 18F FTP SUVR binding in the hippocampus (r = 0.70; P = .01), entorhinal cortex (r = 0.81; P = 02), parahippocampal gyrus (r = 0.74; P = .006), and inferior temporal (r = 0.74; P = .007) regions ( Figure 3 ). No such relationships were significant in noncarriers. In mutation carriers, greater entorhinal and inferior temporal lobe 18F FTP SUVR values were associated ral lobe: r = −0.70; P = .01). Greater inferior temporal tau was also related to worse performance on the CERAD Word List Immediate Learning (r = −0.74; P = .006). Greater PiB binding was only associated with CERAD Word List Delayed Recall (r = −0.70; P = .01).
18F FTP and PiB Binding in Relation to Each Other
Inferior temporal lobe 18F FTP binding was associated with higher mean cortical PiB retention in mutation carriers (r = 0.67; P = .02). In our sample, elevated levels of PiB uptake began around age 30 years. Elevated levels of tau were not observed in mutation carriers younger than 38 years. At this stage, tracer retention was only observed in the entorhinal cortex, and with increasing age of the carrier, higher tau levels were also observed in the inferior temporal and lateral temporal lobe. Flortaucipir F 18 binding in the neocortex was observed in 1 cognitively unimpaired carrier aged 38 years and in all cognitively impaired individuals.
Discussion
In this study, we characterized the spatial pattern and temporal lag cross-sectionally of tau and amyloid deposition in the brains of 24 PSEN1 E280A mutation carriers and noncarriers from the largest known kindred with ADAD. We used PET images with 2 radioligands, 18F FTP, which selectively binds tau aggregates, and carbon 11-labeled PiB, which selectively binds amyloid deposits. Elevated levels of FTP binding were seen within medial [5] years). Studies of PSEN1 mutation carriers allow us to examine cognitively unimpaired individuals who will go on to develop AD in the future with virtual certainty. Previously, we showed that unimpaired mutation carriers from this kindred had significantly lower cerebral metabolic rates for glucose, smaller hippocampal volumes, lower cerebrospinal fluid Aβ1-42 measurements, higher cerebrospinal fluid total tau and tau phosphorylated at threonine 181 levels, and higher plasma Aβ1-42 measurements. 6 To our knowledge, the present study is the first to investigate tau aggregation using PET imaging in this kindred.
The homogeneity of disease course in these mutation carriers allowed us to observe tau and Aβ deposition as a function of individuals' proximity to the expected onset of MCI and dementia. With respect to amyloid, the present findings confirm that Aβ burden in the preclinical stages of ADAD has a similar spatial distribution as in LOAD and begins more than a decade before the onset of clinical symptoms. 29, 30 With respect to tau, elevated levels of FTP binding in medial temporal lobe regions were only observed in individuals who already showed substantial Aβ deposition in cortical regions. Tau aggregation in the neocortex was observed in individuals with early MCI, consistent with the hypothesis that tau's spread beyond the medial temporal lobe is temporally coupled with cognitive impairment. 13 The lack of apparent tau deposition in the neocortex until roughly 6 years prior to MCI combined with the diffuse spatial profile of tau deposition in patients with MCI suggests that tau spreads rapidly once it begins to aggregate in the cortex. The other major PET study of preclinical ADAD is being conducted by the Dominantly Inherited Alzheimer Network (DIAN) group. This study reported PiB data in ADAD in individuals with various AD-causing mutations 31 and has begun to report data on FTP in these individuals. 33 Overall, the results from the Colombia kindred agree with those from DIAN for both FTP and PiB imaging. With respect to Aβ, DIAN showed that, averaging across mutations, individuals with preclinical ADAD showed diffuse cortical PiB elevation years before the estimated age of onset for each individual's family. 31, 32 This result is consistent with the present study and another one based on the Colombian kindred, 6 both of which showed that PiB levels begin to be elevated approximately 15 years prior to estimated onset of MCI. With respect to tau, DIAN has presented preliminary findings, including 11 carriers of various AD-causing mutations 33 and 63 individuals in a study that included LOAD. 34 This study as well as the present study found that tau deposition in ADAD had a similar spatial profile compared with LOAD. The DIAN study also reported an intriguing difference between ADAD and LOAD, where greater tau aggregation was present in individuals with ADAD with a CDR of 0.5 compared with individuals with LOAD with the same CDR. 34 It is unclear how reliable that trend is because the number of participants with CDR of 0.5 in that comparison were not reported in the DIAN presentations. Further, in LOAD, there was notable interindividual variability in tau extension at that CDR. 13 Given the sparse data on tau in LOAD and in both major ADAD studies, it is unclear whether differences in the spatial distribution of tau may be associated with particular mutations and not others.
Limitations
The present study had several limitations. Most importantly, there is uncertainty regarding the extent to which the findings will generalize to LOAD and to other AD-causing mutations. In addition, the present results are based on a relatively small sample size compared with studies of LOAD. This was especially the case when examining the subsamples of unimpaired and impaired individuals within the mutation carrier group. However, because of the rarity of these mutations, the present sample represents, to our knowledge, one of the largest of its kind with amyloid and tau PET data in carriers of a single ADAD mutation. In addition, it is also important to consider that our findings should be interpreted in the context of the inherent limitations of the techniques used. As such, the temporal differences observed between amyloid and tau pathology in this study may be explained in part by limited detection of pathology by PET methods. Because age is predictive of clinical onset in the PSEN1 E280A mutation kindred, cross-sectional assessments across a wide age range in this well-defined cohort are perhaps analogous to what might be expected from the assessment of longitudinal trajectories of biomarker change. However, larger cross-sectional and longitudinal studies are needed to characterize the trajectory of biomarker changes from preclinical to clinical stages.
Conclusions
The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. They also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptomatology of AD, track progression of the disease, and evaluate response to disease-modifying treatments. In addition, this study confirms that clinical symptoms have a greater association with tau pathology than with amyloid pathology. These findings will inform ongoing preclinical trials with ADAD, such as the Alzheimer Prevention Initiative treatment trial of an Aβ-modifying agent. 
